The Global Cardiovascular Risk Consortium
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Jul 18, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Global Cardiovascular Risk Consortium (GCVRC) is a large research study looking at how certain risk factors affect heart health and overall survival. The study collects and analyzes data from over 2.2 million people across many countries. Researchers are focusing on key factors like body weight, blood pressure, cholesterol levels, smoking habits, and diabetes to see how they relate to heart disease and the risk of dying from any cause.
To participate in this study, you need to be between the ages of 65 and up and have information available about the risk factors mentioned. Unfortunately, younger individuals, those with a history of heart disease, or those without complete health data are not eligible. If you join the study, you’ll help researchers understand how these risk factors impact health, which could lead to better prevention and treatment strategies for cardiovascular diseases in the future. Participation is ongoing, and your contribution could make a significant difference in heart health research worldwide.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Population-based individual-level data with available information on the classical cardiovascular risk factors including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as the outcomes of interest.
- Exclusion Criteria:
- • Participants with age below 18 years
- • No information on the outcome of interest
- • No information on the exposure of interest (CVD risk factors)
- • History of CVD at baseline
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Trial Officials
Prof. Dr. med. Stefan Blankenberg
Study Chair
Universitätsklinikum Hamburg-Eppendorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials